Cover Image
市場調查報告書

多囊性腎臟病 (PKD):開發中產品分析

Polycystic Kidney Disease - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192782
出版日期 內容資訊 英文 87 Pages
訂單完成後即時交付
價格
Back to Top
多囊性腎臟病 (PKD):開發中產品分析 Polycystic Kidney Disease - Pipeline Review, H2 2016
出版日期: 2016年10月29日 內容資訊: 英文 87 Pages
簡介

所謂多囊性腎臟病 (PKD)主要是在腎臟內部密集產生囊泡的疾病。主要的症狀有高血壓和背·側腹的疼痛、頭痛、血尿、頻尿、腎功能衰竭等。易罹病因子包含年齡和家族病史等。主要的治療藥有抗高血壓藥和利尿劑等。

本報告提供全球各國治療多囊性腎臟病(PKD)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

多囊性腎臟病概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

多囊性腎臟病:企業開發中的治療藥

多囊性腎臟病:大學/機關研究中的治療藥

多囊性腎臟病:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

多囊性腎臟病:企業開發中的產品

多囊性腎臟病:大學/機關研究中的產品

多囊性腎臟病的治療藥開發企業

  • 3SBio Inc.
  • Angion Biomedica Corp.
  • DiscoveryBiomed, Inc.
  • Endocyte, Inc.
  • IC-MedTech, Inc.
  • Ipsen S.A.
  • Kadmon Corporation, LLC
  • Metabolic Solutions Development Company, LLC
  • NovaTarg Therapeutics, Inc
  • 大塚集團
  • Synta Pharmaceuticals Corp.

多囊性腎臟病:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

多囊性腎臟病:最近的開發平台趨勢

多囊性腎臟病:暫停中的計劃

多囊性腎臟病:開發中止的產品

多囊性腎臟病:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8616IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Kidney Disease - Pipeline Review, H2 2016, provides an overview of the Polycystic Kidney Disease (Genetic Disorders) pipeline landscape.

Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycystic Kidney Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycystic Kidney Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 1, 11 and 2 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively for Polycystic Kidney Disease.

Polycystic Kidney Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Polycystic Kidney Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Polycystic Kidney Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Polycystic Kidney Disease (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Polycystic Kidney Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Polycystic Kidney Disease Overview
  • Therapeutics Development
    • Pipeline Products for Polycystic Kidney Disease - Overview
    • Pipeline Products for Polycystic Kidney Disease - Comparative Analysis
  • Polycystic Kidney Disease - Therapeutics under Development by Companies
  • Polycystic Kidney Disease - Therapeutics under Investigation by Universities/Institutes
  • Polycystic Kidney Disease - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Polycystic Kidney Disease - Products under Development by Companies
  • Polycystic Kidney Disease - Products under Investigation by Universities/Institutes
  • Polycystic Kidney Disease - Companies Involved in Therapeutics Development
    • Angion Biomedica Corp.
    • Aptevo Therapeutics Inc
    • DiscoveryBiomed, Inc.
    • Endocyte, Inc.
    • IC-MedTech, Inc.
    • Ipsen S.A.
    • Kadmon Corporation, LLC
    • ManRos Therapeutics
    • Metabolic Solutions Development Company, LLC
    • NovaTarg Therapeutics, Inc
    • Otsuka Holdings Co., Ltd.
    • XORTX Pharma Corp.
  • Polycystic Kidney Disease - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (ascorbic acid + menadione) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANG-3070 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CIM-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CR-8 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DBM-43H11 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Polycystic Kidney Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EC-0371 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JP-153 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lanreotide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • menadione sodium bisulfite - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MSDC-0160 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MSDC-0602 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • oxypurinol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pyrimethamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate AMPK for Polycystic Kidney Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STA-2842 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tesevatinib tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TNFR x TWEAKR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tolvaptan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Polycystic Kidney Disease - Dormant Projects
  • Polycystic Kidney Disease - Discontinued Products
  • Polycystic Kidney Disease - Product Development Milestones
    • Featured News & Press Releases
      • Jan 11, 2016: Scottish Medicines Consortium Issues Positive Advice For First Ever Treatment For Autosomal dominant polycystic kidney disease
      • Nov 02, 2015: Kadmon to Present Clinical Data on Tesevatinib for the Treatment of Polycystic Kidney Disease at ASN's Kidney Week 2015
      • May 28, 2015: Otsuka's JINARC the First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease
      • Apr 14, 2015: DiscoveryBioMed is developing a novel and unprecedented "dual action" small molecule monotherapy for all cystic fibrosis (CF) patients and for other chronic larger market or rare lung and vascular diseases
      • Mar 18, 2015: Metabolic Solutions Development Company Highlights Plans for MSDC-0602 in NASH and Polycystic Kidney Disease
      • Feb 27, 2015: CHMP Recommends JINARC (Tolvaptan) for Approval in EU: The First Pharmaceutical Treatment for Autosomal Dominant Polycystic Kidney Disease
      • Feb 26, 2015: First-Ever Treatment Approved in Canada for Adults Living with ADPKD, a Life-Threatening Kidney Disease
      • Sep 15, 2014: DiscoveryBioMed Awarded A Dual SBIR Awards For Drug Discovery, Validation, Optimization And Development For Autosomal Dominant Polycystic Kidney Disease, The Leading Genetic Cause Of Dialysis And Transplantation Worldwide
      • Jun 19, 2014: Kadmon Corporation Initiates Phase 2a Portion of KD020 Study in Autosomal Dominant Polycystic Kidney Disease
      • Jun 11, 2014: Otsuka Pharmaceutical Initiates Phase 3 Clinical Trial Of Tolvaptan In Patients With Autosomal Dominant Polycystic Kidney Disease
      • May 23, 2014: Launch in Japan of Samsca 30 mg Tablet Formulation for Patients With Autosomal Dominant Polycystic Kidney Disease, an Orphan Disease
      • Mar 24, 2014: Otsuka Pharmaceutical's Samsca Approved in Japan as the World's First Drug Therapy for ADPKD, a Rare Kidney Disease
      • Dec 27, 2013: European Medicines Agency Accepts Otsuka's Marketing Authorisation Application for Tolvaptan, an Investigational Compound for Autosomal Dominant Polycystic Kidney Disease
      • Aug 29, 2013: Otsuka Receives Complete Response Letter from U.S. Food and Drug Administration for Tolvaptan for Use in Patients with Autosomal Dominant Polycystic Kidney Disease
      • Aug 05, 2013: U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee Recommends Not to Approve Otsuka Pharmaceutical's Tolvaptan for Use in Autosomal Dominant Polycystic Kidney Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Polycystic Kidney Disease, H2 2016
  • Number of Products under Development for Polycystic Kidney Disease - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Polycystic Kidney Disease - Pipeline by Angion Biomedica Corp., H2 2016
  • Polycystic Kidney Disease - Pipeline by Aptevo Therapeutics Inc, H2 2016
  • Polycystic Kidney Disease - Pipeline by DiscoveryBiomed, Inc., H2 2016
  • Polycystic Kidney Disease - Pipeline by Endocyte, Inc., H2 2016
  • Polycystic Kidney Disease - Pipeline by IC-MedTech, Inc., H2 2016
  • Polycystic Kidney Disease - Pipeline by Ipsen S.A., H2 2016
  • Polycystic Kidney Disease - Pipeline by Kadmon Corporation, LLC, H2 2016
  • Polycystic Kidney Disease - Pipeline by ManRos Therapeutics, H2 2016
  • Polycystic Kidney Disease - Pipeline by Metabolic Solutions Development Company, LLC, H2 2016
  • Polycystic Kidney Disease - Pipeline by NovaTarg Therapeutics, Inc, H2 2016
  • Polycystic Kidney Disease - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Polycystic Kidney Disease - Pipeline by XORTX Pharma Corp., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Polycystic Kidney Disease - Dormant Projects, H2 2016
  • Polycystic Kidney Disease - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Polycystic Kidney Disease, H2 2016
  • Number of Products under Development for Polycystic Kidney Disease - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top